Scientific article
English

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

Published inThe New England journal of medicine, vol. 367, no. 25, p. 2396-2406
Publication date2012
Abstract

Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti-interleukin-1β monoclonal antibody, in two trials.

Keywords
  • Adolescent
  • Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
  • Antibodies, Monoclonal/adverse effects/therapeutic use
  • Arthritis, Juvenile Rheumatoid/complications/drug therapy
  • Child
  • Child, Preschool
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Glucocorticoids/therapeutic use
  • Humans
  • Infection/chemically induced
  • Interleukin-1beta/antagonists & inhibitors
  • Kaplan-Meier Estimate
  • Macrophage Activation Syndrome/etiology
  • Male
  • Methotrexate/therapeutic use
  • Neutropenia/chemically induced
  • Thrombocytopenia/chemically induced
Citation (ISO format)
RUPERTO, Nicolino et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. In: The New England journal of medicine, 2012, vol. 367, n° 25, p. 2396–2406. doi: 10.1056/NEJMoa1205099
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN0028-4793
730views
0downloads

Technical informations

Creation17/10/2013 13:55:00
First validation17/10/2013 13:55:00
Update14/03/2023 20:34:11
Status update14/03/2023 20:34:10
Last indexation30/10/2024 14:45:04
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack